Colin Havenar-Daughton | Director of Immunology
Vir Biotechnology

WVIC/WAC Pre-Congress Workshops - Nov 28 @ 14:00

Workshop B [Room: Constellation B]

Antibody Drug Discovery for Infectious Diseases

2pm – 5pm

2pm: Chair opening remarks: Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

Presentations 2.10pm – 4pm:

Shark-derived nanobodies for diagnostic and therapeutic use

Dr Helen Dooley, Assistant Professor, University of Maryland School of Medicine

Developing high affinity, high avidity, IgM antibodies for the prevention and treatment of infectious diseases

Dr Sha Ha, VP, CMC, IGM Biosciences

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants 

Dr Shivshankar “Shankar” Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus

Dr Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research

La Jolla Institute for Immunology, LaJolla Institute

Tackling viral infections by human monoclonal antibodies

Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

4.00-5:00pm Panel & Q&A with speakers: Overcoming hurdles in antibodies discovery and development against viral infection

• How to develop antibodies that are resistant to viral mutations? 
• How can the cost be justified if other therapeutics are available?
• What effects has the pandemic had in increasing desire for therapeutic antibodies
• The role of FC and FC modifications to enhance effector function

Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

×

Colin Havenar-Daughton / Workshop B [Room: Constellation B]

Colin Havenar-Daughton, Director of Immunology,
Vir Biotechnology

Colin Havenar-Daughton is a Director of Immunology at Vir Biotechnology. He earned his PhD degree in Immunology from the University of Washington. Colin conducted postdoctoral studies in Shane Crotty’s laboratory at the La Jolla Institute, where he focused on the immunological underpinnings of...

CloseMore

Sha Ha, VP CMC, IGM Infectious Diseases, Inc.

×

Sha Ha / Workshop B [Room: Constellation B]

Sha Ha, VP CMC,
IGM Infectious Diseases, Inc.

Sha Ha is the Vice President of CMC at IGM Biosciences. She oversees drug substance and drug product development as well as analytical development in the Doylestown PA site. Before joining IGM, Sha was the director of Vaccine Process Development and Commercialization at Merck.  She managed Phase 3...

CloseMore

Shivshankar Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

×

Shivshankar Sundaram / Workshop B [Room: Constellation B]

Shivshankar Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics,
Lawrence Livermore National Laboratory

Shankar Sundaram currently serves as the Director for the Center for Bioengineering at the Lawrence Livermore National Laboratory. In this capacity, he leads the laboratory’s Bioengineering strategy and technology development activities that address critical challenges in health and biosecurity. He ...

CloseMore

Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research, La Jolla Institute

×

Haoyang Li / Workshop B [Room: Constellation B]

Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research,
La Jolla Institute

Haoyang recieved his PhD in Pathogenic Organisms from Fudan University and works at La Jolla Institute.

Close

Helen Dooley, Assistant Professor, University of Maryland School of Medicine

×

Helen Dooley / Workshop B [Room: Constellation B]

Helen Dooley, Assistant Professor,
University of Maryland School of Medicine

Helen Dooley obtained her PhD at the University of Aberdeen, UK. After a post-doc at the University of Maryland, Baltimore, USA, she spent a few years working in the Global Biotherapeutics division of Wyeth, retaining this role with Pfizer post-takeover. She is now Assistant Professor at University ...

CloseMore